Perspective Therapeutics [212Pb]VMT01 melanoma trial data set for SITC 2026 presentation

By Public Technologies
  • Perspective Therapeutics flagged [²¹²Pb]VMT01 phase I/IIa melanoma data accepted for presentation at SITC 2026 in Phoenix.
  • Results were already presented at ASCO 2026, with additional disclosure scheduled for Nov. 6, 2026.
  • Interim readout showed early signs of tumor control in heavily pretreated patients, with safety broadly manageable.
  • Trial evaluates [²¹²Pb]VMT01 alone, with a separate arm testing combination therapy with Bristol Myers Squibb’s nivolumab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021146PRIMZONEFULLFEED9838758) on October 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk